 INmune Bio, Inc. INMB the Company, a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, announced presentation of a study demonstrating the combination of INB03 with lapatinib reverses resistance to therapy in trastuzumab resistant HER2 breast cancer. The work lays the groundwork for INmune Bios planned Phase II trial and, was chosen for an oral presentation at the New York Academy of Science Frontiers in Cancer Immunotherapy 2020 publication on Monday, 11 May. Sophi Bruni, a doctoral student in the laboratory of Dr. Roxana Schillaci, in the Lab of Molecular Mechanisms, Instituto de Biología y Medicina Experimental-CONICET, Argentina will be presenting the work. 